Abstract: Objective To observe the efficacy and safety of Luminal B（HER-2 positive） advanced breast cancer patients who receive fulvestrant combined with trastuzumab after prior aromatase inhibitors and disease controlled by chemotherapy. Methods There were 11 advanced aromatase inhibitors Luminal B breast cancer patients who received fulvestrant plus trastuzumab as maintenane therapy， after they benefited from palliative chemotherapy. Fulvestrant regimen was 500 mg every month plus 500 mg on day 14 of month 1 and rastuzumab regimen was 6mg／kg every 3 weeks. Results All patients were available for evaluation. Of the 11 patients， 1 case got complete response（CR）， 1 case had partial response（PR） and 5 cases had stable disease（SD）. The average PFS was 8.4 months. The objective response rate was 18.2％ and disease control rate was 63.6％. The treatment was well tolerated and no severe adverse effects were observed. Conclusion The combination of fulvestrant and trastuzumab regimen is effective and tolerable in the treatment of advanced Luminal B（HER-2 positive） breast cancer patients who resistant to aromatase inhibitors after palliative chemotherapy to prolong the progression-free survival time.